Olympus Aktie

15,12EUR -0,04EUR -0,26%
Olympus für 0 Euro bei ZERO ordern (zzgl. Spreads)
WKN: 856840 / ISIN: JP3201200007
<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 89,84
Nomura Asset Management Co., Ltd. 7,04
Baillie Gifford & Co. 5,57
Capital Research & Management Co. (World Investors) 5,23
American Funds EuroPacific Growth Fund 3,52
Olympus Corp. 3,51
Sumitomo Mitsui Banking Pension Fund 3,35
Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) 3,03
Nomura Asset NEXT FUNDS TOPIX ETF (1306) 2,84
Nippon Life Insurance Co. 1,81
Mitsubishi UFJ Asset Management Co., Ltd. 1,71
Dodge & Cox International Stock Fund 1,68
Nikko Exchange Traded Index Fund 225 1,46
First Sentier Investors (Singapore) 0,73

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2020 2021 2022 2023 2024
Personal am Ende des Jahres 35 174 31 653 31 557 32 844 28 838
Umsatz pro Mitarbeiter in Mio. EUR 22,67 23,08 27,53 26,85 32,46

Bilanz (in Mio. JPY) - Aktiva

2020 2021 2022 2023 2024
Summe Umlaufvermögen 506 707 580 162 694 605 726 357 800 340
Summe Anlagevermögen 508 956 600 855 663 394 781 951 733 876
Summe Aktiva 1 015 663 1 181 017 1 357 999 1 508 308 1 534 216

Bilanz (in Mio. JPY) - Passiva

2020 2021 2022 2023 2024
Gesamtverschuldung/ -verbindlichkeiten 322 658 432 520 451 142 397 219 360 559
Summe Fremdkapital 643 705 785 537 846 637 867 074 777 030
Summe Eigenkapital 371 958 395 480 511 362 641 234 757 186
Summe Passiva 1 015 663 1 181 017 1 357 999 1 508 308 1 534 216

Adresse

Shinjuku Monolith, 163-0914 Tokyo
Telefon +81 (3) 3340-2111
Fax +81 (3) 3340-2062
Internet http://www.olympus.co.jp

Management

Akira Hasegawa
Executive Officer, Head-Research & Development
André Roggan
Executive Officer & Chief Technology Officer
Boris Shkolnik
Chief Quality Officer & Executive Officer
David Robert Hale
Outside Director
Eva Gardyan-Eisenlohr
Global Chief Compliance Officer
Gabriela Kaynor
Chief Strategy Officer & Executive Officer
Gary John Pruden
Independent Director
Jimmy C. Beasley
Independent Outside Director
John de Csepel
Chief Medical Officer
Katsuyuki Saito
Executive Officer, Head-Corporate R&D
Kohei Kan
Outside Director
Luann M. Pendy
Outside Director
Neil Boyden Tanner
Global General Counsel
Sachiko Ichikawa
Outside Director
Shigeto Ohtsuki
Executive Officer & Head-Human Resources
Stephen Mark Kneebone
Chief Information Officer & Executive Officer
Sumitaka Fujita
Independent Outside Director
Takaaki Sakurai
Vice President-Investor Relations
Takayuki Aoyagi
Vice President-Accounting
Tatsuro Kosaka
Outside Director
Tatsuya Izumi
Chief Financial Officer & Executive Officer
Tetsuo Kobayashi
Chief Manufacturing & Supply Officer
Tomohisa Sakurai
Executive Officer & Head-Therapeutic Solutions
Toshihiko Okubo
Outside Director
Wenlei Yang
Chief Diversity, Equity & Inclusion Officer
Yasumasa Masuda
Independent Outside Director
Yasuo Takeuchi
Executive Chairman & Chief Executive Officer
Yasushi Shingai
Outside Director
Yoshio Tashiro
Executive Officer & Head-Technology Strategy